

Neola Medical's Q2 2026 Report Presentation hosted by Investor Studios

Catch up on the key highlights from Neola Medical's Q2 2026 report. CEO Hanna Sjöström shares reflections on the company's clinical progress, strengthened financing and sharpened strategic focus. CFO David Folkesson presents the financial results for the quarter.

Watch the presentation and Q&A session here: <https://www.youtube.com/live/r5ppKjlvrec>

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

David Folkesson, CFO

email: david.folkesson@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung collapse in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on near-infrared light measurements in the lungs. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Neola Medical's Q2 2026 Report Presentation hosted by Investor Studios](#)